AP NEWS

Opioid Induced Constipation Drug Development 2018 - Pipeline Analysis Report - ResearchAndMarkets.com

July 12, 2018

DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “2018 Opioid Induced Constipation (OIC) Drug Development- Pipeline Analysis Report” report has been added to ResearchAndMarkets.com’s offering.

With an estimated $600 million market value, the Opioid Induced Constipation (OIC) is one of the most common gastrointestinal conditions, presenting robust opportunities for development of treatment options.

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Opioid Induced Constipation (OIC) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Opioid Induced Constipation (OIC) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Opioid Induced Constipation (OIC) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Key Topics Covered:

1 Opioid Induced Constipation Pipeline Analysis

2 Opioid Induced Constipation- Company Wise Pipeline Analysis

3 Opioid Induced Constipation R&D Pipeline Snapshots

4 Recent Developments in Opioid Induced Constipation Pipeline

5 Appendix

Companies Featured

Acacia Pharma Algobate AG Amherst Pharmaceuticals LLC Braeburn Pharmaceuticals Camurus AB Ironwood Pharmaceuticals Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Kwang Dong Pharmaceutical Co Ltd Shionogi & Co Ltd Suda Ltd Synergy Pharmaceuticals Inc Theravance Biopharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/d7r9pl/opioid_induced?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005440/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Gastrointestinal Drugs ,Addiction Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/12/2018 08:41 AM/DISC: 07/12/2018 08:41 AM

http://www.businesswire.com/news/home/20180712005440/en

AP RADIO
Update hourly